This is the authors' abstract. We don't add key points for this paper.
The mandatory replacement of chlorofluorocarbons (CFCs) with ozone-friendly propellants, such as hydrofluoroalkanes (HFAs), has provided an opportunity to optimize aerosol design and improve drug delivery to pulmonary tissue. Asthma is an inflammatory disorder of the lungs that appears to affect both small and large airways, so ideally, inhaled corticosteroid should reach both central and peripheral sites. This review considers the development of an aerosol system containing beclomethasone dipropionate in hydrofluoroalkane-134a (HFA) propellant (Qvar, 3M Health Care, Loughborough, UK) designed to target medication delivery throughout the bronchopulmonary tree and to improve the therapeutic ratio (topical efficacy: systemic safety), thereby offering potential clinical benefits to asthma patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
David Donnell (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: